A phase 1 trial of SIM0613.
Latest Information Update: 09 Jan 2026
At a glance
- Drugs Antineoplastics (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 09 Jan 2026 New trial record
- 22 Dec 2025 According to an Ipsen media release, SIM 0613 is expected to enter Phase I clinical development in H2 2026.